Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

CRBU
Caribou Biosciences, Inc. Common Stock
stock NASDAQ

Market Open
Aug 5, 2026 12:17:13 PM EDT
1.64USD+4.459%(+0.07)453,272
1.63Bid   1.64Ask   0.01Spread
Pre-market
Aug 5, 2026 8:41:30 AM EDT
1.59USD+1.146%(+0.02)1,553
After-hours
Aug 4, 2026 4:58:30 PM EDT
1.59USD+1.274%(+0.02)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 18, 2022
08:14AM EST  Caribou Biosciences Appoints Syed Rizvi, M.D., As Chief Medical Officer   Benzinga
08:00AM EST  Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical   GlobeNewswire Inc
Jan 5, 2022
11:07AM EST  Stocks That Hit 52-Week Lows On Wednesday   Benzinga
Jan 4, 2022
04:05PM EST  Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribous president and chief executive officer, will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:45 am ET.   GlobeNewswire Inc
Dec 14, 2021
02:51PM EST  CRISPR Therapeutics Shares Move Higher; Elon Musk, Responding To Gene Editing Article, Says 'This is the revolution in medicine'   Benzinga
Dec 8, 2021
10:11AM EST  Caribou Biosciences shares were trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $36 price target.   Benzinga
Dec 1, 2021
10:08AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021   Benzinga
05:00AM EST  Oppenheimer Initiates Coverage On Caribou Biosciences with Outperform Rating, Announces Price Target of $36   Benzinga
Nov 30, 2021
04:51PM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021   Benzinga
04:43PM EST  HC Wainwright & Co. Initiates Coverage On Caribou Biosciences with Buy Rating, Announces Price Target of $28   Benzinga
Nov 17, 2021
04:05PM EST  Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribous president and chief executive officer, will participate in the following upcoming investor conferences.   GlobeNewswire Inc
Nov 15, 2021
11:20AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021   Benzinga
11:10AM EST  Citigroup Upgrades Caribou Biosciences to Buy, Maintains $27 Price Target   Benzinga
Nov 9, 2021
05:55PM EST  Caribou Biosciences Q3 Net Loss $21M vs Net Loss $7.9M In Same Qtr. Last Year   Benzinga
Nov 8, 2021
09:00AM EST  Caribou Biosciences Appoints Dara Richardson-Heron, M.D., to its   GlobeNewswire Inc
Oct 21, 2021
12:10PM EDT  Caribou Biosciences To Present At Jefferies Summit On Wednesday, Oct. 27 At 1 p.m. EDT, At Barclays Summit Monday, Nov. 15, 9:30 a.m. EDT   Benzinga
Oct 20, 2021
04:00PM EDT  Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribous President and Chief Executive Officer, will present a company overview at the following upcoming investor conferences.   GlobeNewswire Inc
Oct 14, 2021
05:52AM EDT  Caribou Biosciences Chief Scientific Officer Steven Kanner Reported Purchase of 229,720 Shares Pursuant to Exercise of a Stock Option in a Form 4 Filing on Wednesday   Benzinga
Sep 29, 2021
04:05PM EDT  Caribou Biosciences Appoints Biotechnology Industry Veteran Ran   GlobeNewswire Inc
Sep 27, 2021
04:09PM EDT  Caribou Biosciences To Participate In The Chardan Virtual 5th Annual Genetic Medicines Conference On Monday, October 4, 2021, At 5:00 pm ET   Benzinga
04:05PM EDT  Caribou Biosciences to Participate in the Chardan Virtual 5th   GlobeNewswire Inc
Sep 8, 2021
07:32AM EDT  The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod   Benzinga
Sep 2, 2021
04:10PM EDT  Caribou Biosciences Q2 Net Loss $14.3M vs Net Loss $1.9M In Same Qtr. Last year, Licensing, Collab Sales $1.5M vs $8.5M Year Over Year   Benzinga
04:09PM EDT  Caribou Biosciences Announces Publication Of Data Demonstrating High Specificity Genome Editing With Its Proprietary chRDNA Technology   Benzinga
04:05PM EDT  Completed upsized initial public offering of common stock, raising$349.6 million in gross proceeds including full exercise of underwriters option to purchase additional shares   GlobeNewswire Inc
04:05PM EDT  Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribous proprietary chRDNA technology for therapeutic applications   GlobeNewswire Inc
Sep 1, 2021
08:00AM EDT  Caribou Biosciences to Participate in Citis 16Th   GlobeNewswire Inc
Aug 25, 2021
04:00PM EDT  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has appointed Nancy Whiting, Pharm.D., to its board of directors. Dr. Whiting brings over 17 years of biotechnology industry expertise in drug and portfolio development, as well as significant strategic leadership experience.   GlobeNewswire Inc
Aug 24, 2021
08:09AM EDT  The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal   Benzinga
Aug 17, 2021
10:09AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 17, 2021   Benzinga
08:10AM EDT  Citigroup Initiates Coverage On Caribou Biosciences with Neutral Rating, Announces Price Target of $27   Benzinga
08:07AM EDT  B of A Securities Initiates Coverage On Caribou Biosciences with Buy Rating, Announces Price Target of $30   Benzinga
07:13AM EDT  SVB Leerink Initiates Coverage On Caribou Biosciences with Outperform Rating, Announces Price Target of $32   Benzinga
Aug 15, 2021
12:16PM EDT  The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow   Benzinga
11:06AM EDT  The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 6, 2021
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Jul 28, 2021
10:14AM EDT  The IPO Recap Party Is Everything But Over   Benzinga
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 23, 2021
11:48AM EDT  Caribou Biosciences Shares Open For Trade At $17.65; IPO Priced At $16/Share   Benzinga
09:06AM EDT  Caribou Biosciences Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $16/Share   Benzinga
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 22, 2021
09:17PM EDT  Caribou Biosciences Prices Upsized IPO Of 19 Mln Shares At $16.00/shr   RTTNews
09:09PM EDT  Caribou Biosciences Announces Pricing of Upsized Initial Public Offering   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC